Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CNS Metastases in Patients With Non–Small-Cell Lung Cancer and <i>ALK</i> Gene Rearrangement

2 Dec 2015

Abstract excerpt

Despite the improved outcome with TKIs in patients with ALK gene rearrangement, CNS metastases remains a significant challenge. Approximately, 20% to 35% of such patients present with brain metastases. 2,5 Moreover, the CNS is a frequent site of disease progression in patients who receive crizotinib. The CNS is frequentlyasiteofdiseaseprogression,whereupto60%ofpatients develop metastases during treatment with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26628475
DOI: 10.1200/jco.2015.63.9682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CNS Metastases in Patients With Non–Small-Cell Lung Cancer and <i>ALK</i> Gene RearrangementPMID 26628475Read ↗

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?Semantic proximity Read ↗

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.Semantic proximity Read ↗

Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases.Semantic proximity Read ↗

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.Semantic proximity Read ↗

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.Semantic proximity Read ↗

A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Semantic proximity Read ↗

Combined BBB-penetrant tyrosine kinase inhibitor and intracranial radiotherapy versus BBB-penetrant tyrosine kinase inhibitor alone for the treatment of EGFR-mutated non-small cell lung cancer patients with brain metastasesSemantic proximity Read ↗

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.